更正：接受酪氨酸激酶抑制剂治疗的慢性髓性白血病患者的并发症和预后：来自匈牙利的一项真实世界、全国范围的回顾性研究。

IF 2.3 4区医学 Q3 ONCOLOGY

Pathology & Oncology Research Pub Date : 2024-03-21 eCollection Date: 2024-01-01 DOI:10.3389/pore.2024.1611758

Peter Batar, Hussain Alizadeh, Gyorgy Rokszin, Zsolt Abonyi-Toth, Judit Demeter

引用次数: 0

摘要

[此处更正了文章 DOI：10.3389/pore.2024.1611497]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Corrigendum: Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary.

[This corrects the article DOI: 10.3389/pore.2024.1611497.].

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pathology & Oncology Research 医学-病理学

CiteScore

6.30

自引率

0.00%

发文量

134

审稿时长

4-8 weeks

期刊介绍： Pathology & Oncology Research (POR) is an interdisciplinary Journal at the interface of pathology and oncology including the preclinical and translational research, diagnostics and therapy. Furthermore, POR is an international forum for the rapid communication of reviews, original research, critical and topical reports with excellence and novelty. Published quarterly, POR is dedicated to keeping scientists informed of developments on the selected biomedical fields bridging the gap between basic research and clinical medicine. It is a special aim for POR to promote pathological and oncological publishing activity of colleagues in the Central and East European region. The journal will be of interest to pathologists, and a broad range of experimental and clinical oncologists, and related experts. POR is supported by an acknowledged international advisory board and the Arányi Fundation for modern pathology.